跳至主要内容
临床试验/CTRI/2024/01/062163
CTRI/2024/01/062163尚未招募4 期

An investigator initiated, single center, single arm, open-label, cross-sectional study to assess clinical impact of adjunctive cariprazine in Indian patientswith Major Depressive Disorder. - BOOST

ot Applicable0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
ot Applicable

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • All patients must meet all of the following criteria for enrollment in the study:
  • 1) Clinical cases of Difficult to treat depression showing incomplete response (less than 50% MADRS scores reduction) to SSRI monotherapy receiving Cariprazine
  • 2) Clinical cases receiving Cariprazine with follow-up data for 12 weeks

排除标准

  • If patient meeting any of the study exclusion criteria should be excluded from study
  • 1) Clinical cases receiving Cariprazine with antecedent history or cause or diagnoses of personality disorder, comorbidities including bipolar disorder, schizophrenia, substance abuse disorder, dementia or other neurodegenerative diseases significantly impacting cognitive functioning, or mood disorders due to an underlying general medical condition
  • 2) Patients currently receiving ECT or Psychotherapy since last six weeks

研究者

发起方
ot Applicable

相似试验